Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer

2018106 citationsJournal Articlegold Open Access

Authors

Christian Rolfo · University of Maryland, Baltimore

Paolo Manca · Università Campus Bio-Medico

Roberto Salgado · Institut Jules Bordet

Peter A. van Dam · Antwerp University Hospital

Amélie Dendooven · Antwerp University Hospital

Jose Ferri Gandia · Hospital General Universitario De Valencia

Annemie Rutten

Abstract

Our MTB allows patients with refractory cancer to be included in clinical trials and improves the precision of clinical decisions compared with a standardised set of mutation-driven recommendations.

Topics & Keywords

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 3, Issue 5, pp. e000398-e000398

DOI: 10.1136/esmoopen-2018-000398

Field-Weighted Citation Impact: 4.37